Adverse events observed in the trial-and generally associated with treatments of this condition-included vein inflammation (phlebitis) and burning or tingling (paresthesia) in the treatment zone.
Initial symptoms are excessive salivation, perspiration, vomiting, dizziness, weakness and paresthesia in the extremities and around the mouth, low blood pressure and sinus bradycardia.
The other mechanism is that the alkalosis causes decreased freely ionized blood calcium, thereby causing cell membrane instability and subsequent vasoconstriction and paresthesia.
